Dermatology company Botanix Pharmaceuticals (ASX: BOT) has safely navigated the US Food and Drug Administration (FDA) mid-cycle review with sofpironium bromide.
Botanix’ lead product is in development for the treatment of primary axillary hyperhidrosis, a medical condition where excessive sweating occurs beyond what is needed to maintain normal body temperature.
"This is an exciting chapter for Botanix"No significant issues have been identified as a result of the FDA’s review. This includes no major clinical safety issues, no risk management issues, or advisory board requirements.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze